
Articles

2012-8

Clinical Applicability of the Macular Degeneration Detection Device (MDD-2): a Novel Photostress Recovery Measurement Device

James Loughman

Technological University Dublin, james.loughman@tudublin.ie

Ciara Hewitt

Technological University Dublin

Claire Judge

Technological University Dublin

See next page for additional authors

Follow this and additional works at: <https://arrow.tudublin.ie/otpomart>



Part of the [Optometry Commons](#)

Recommended Citation

Loughamn, J., Hewitt, C., Judge, C., Martin, L., Moulds, C., Davison, P.: Clinical Applicability of the Macular Degeneration Detection Device (MDD-2): a Novel Photostress Recovery Measurement Device. *Clinical and Experimental Optometry*, 28 October, 2012. DOI:10.1111/j.1444-0938.2012.00813.x

This Article is brought to you for free and open access by ARROW@TU Dublin. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@TU Dublin. For more information, please contact arrow.admin@tudublin.ie, aisling.coyne@tudublin.ie.



This work is licensed under a [Creative Commons Attribution-NonCommercial-Share Alike 4.0 License](#)

Authors

James Loughman, Ciara Hewitt, Claire Judge, Louise Martin, Claire Moulds, and Peter Davison

CLINICAL AND EXPERIMENTAL
OPTOMETRY

RESEARCH PAPER

Clinical applicability of the Macular Degeneration Detection Device (MDD-2): a novel photostress recovery measurement device

Clin Exp Optom 2012

DOI:10.1111/j.1444-0938.2012.00813.x

James Loughman*[†] PhD
Ciara Hewitt* BSc
Claire Judge* BSc
Louise Martin* BSc
Claire Moulds* BSc
Peter A Davison* PhD

* Optometry Department, College of Sciences & Health, Dublin Institute of Technology, Dublin, Ireland

[†] African Vision Research Institute, Faculty of Health Sciences, University of KwaZulu Natal, Durban, South Africa
E-mail: james.loughman@dit.ie

Background: Diseases affecting the macula, such as age-related macular degeneration (AMD), diabetic retinopathy and central serous retinopathy can result in impaired photostress recovery time (PSRT) despite normal visual acuity and fundoscopic appearance. The MDD-2 Macular Degeneration Detection Device is a novel flash photostress recovery device. In this study, we examine the repeatability of the MDD-2 in a normal population and its suitability for incorporation into routine clinical practice.

Methods: One hundred (60 female) subjects (mean age 35 ± 8 years; range 18 to 66 years) were recruited to partake in this study. The photostress recovery time was measured using the MDD-2 on three occasions in the dominant eye and one final occasion in the non-dominant eye to assess measurement repeatability. All subjects were in good ocular health. Visual acuity and iris colour were recorded for each participant.

Results: Repeated measures analysis of variance revealed a statistically significant learning effect on intra-measurement repeatability ($p < 0.01$). Although paired t-test analysis revealed statistically significant differences between repeated measures both within and between eyes ($p < 0.05$ for all) the correlation between repeat measurements is statistically significant ($p < 0.05$ for all), and the coefficient of repeatability reaches clinically acceptable levels once the initial photostress recovery time, which demonstrated increased variability and latency compared to all subsequent measures, is excluded.

Conclusion: The MDD-2 provides highly repeatable measurements of photostress recovery time among young naïve subjects, following verbal explanation of the task and only one 'practise' measurement. The measurement is also highly repeatable between eyes, providing a potential immediate clinical biomarker of ocular health.

Submitted: 26 January 2012

Revised: 18 July 2012

Accepted for publication: 2 August 2012

Key words: age-related macular degeneration, macula, MDD-2, photostress recovery time

Early detection of visual loss, such as is associated with macular disease, including age-related macular degeneration (AMD), diabetic retinopathy and central serous retinopathy, is of prime concern to eye-care practitioners and health-care

providers for a number of reasons, which include:

1. the increasing prevalence of ocular disease¹⁻³
2. the likely increase in consequential visual impairment and blindness^{4,5}
3. the possibilities for retarding disease progression through supplementation⁶ and
4. recent advances in pharmacologic management of conditions, such as AMD, which are best applied at the

earliest stages of the development of abnormal pathology.⁷

In addition, it is also important that functional biomarkers provide prognostic information and guide clinical decisions around the need for treatment and its success.^{8,9}

Although visual acuity (VA) alone is an inadequate marker of visual function in macular disease,⁹ other biomarkers including photopic and scotopic light sensitivity,¹⁰ flicker sensitivity,¹¹ colour vision,¹² contrast sensitivity,¹³ dark adaptation^{14,15} and photostress recovery¹⁶ can provide additional capacity to detect the early signs of retinal degeneration. It has been suggested that these early signs are partially attributable to an increased effect of intraocular scattered light in the diseased eye,¹⁷⁻¹⁹ along with excessive photoreceptor bleaching due to the relative lack of photo-protection in the affected retina. In particular, photostress recovery time (PSRT) has been shown to be adversely affected by retinal and macular disease.^{16,20,21}

Photostress recovery time describes the time required to regain normal visual function after viewing a light source so intense as to bleach the visual pigments and saturate the response of the macular photoreceptors, and therefore cause transitory loss of vision.^{22,23} This dynamic assessment of macular function, originally described for the assessment of central serous retinopathy²⁴ is an excellent indicator of retinal integrity, as normal recovery depends on an efficient and intact underlying retinal photoreceptor and pigment epithelial function.^{25,26} Therefore, it can be used to indentify insidious, pre-clinical macular disease and potentially in advance of a reduction in VA, a defect on Amsler grid²⁷ or other clinical manifestations. A recent evaluation of potential biomarkers of early AMD found that PSRT achieved high diagnostic capacity and provided the optimal qualitative assessment of visual function in early AMD.¹⁶ Abnormal PSRTs may also be used to differentiate retinal/macular from neural/optic nerve disease.^{27,28}

Macular photostress can be induced either using a brief flash of intense light

delivered to the macula or using a more sustained and lower-intensity light source such as the ophthalmoscope. Flash recovery testing is effective in the detection of early macular disease.²⁹ The MDD-2 Macular Degeneration Detection Device is a novel flash photostress recovery device. This device is capable of detecting functional visual loss in AMD and diabetic maculopathy.²⁰ No previous study has explored the clinical applicability of this test in terms of learning and repeatability. In this study, we examine the repeatability of the MDD-2 in a normal population and its suitability for incorporation into routine clinical practice.

METHODS

One hundred subjects (60 female) participated in this study (one additional subject was excluded on the basis of the presence of ocular pathology), which was approved by the Research Ethics Committee at Dublin Institute of Technology (DIT). Informed consent was obtained from each volunteer and the experimental procedures adhered to the tenets of the Declaration of Helsinki.

The study was conducted in the Vision Science Laboratory and National Optometry Centre at DIT. Recruitment of subjects was by word of mouth. All subjects were aged between 18 and 66 years, in good general (by self-report) and ocular (determined by ophthalmoscopy) health and with logMAR visual acuity of at least 0.2 (6/9) in the study eye. Exclusion criteria included any sign of retinal or ocular abnormality, any known systemic health condition and logMAR visual acuity less than 0.2. A computer-generated logMAR test chart (Thomson 2000 Pro; Thomson Software Solutions, Hatfield, United Kingdom) was used to determine logMAR acuity. Iris colour was recorded using an iris colour classification scheme, with iris colour matched to standard colour photographs and classified into one of five categories (grey, blue, green, light brown, brown) as described by Seddon.³⁰ All subjects recruited into the study were naïve to the MDD-2 test.

Photostress recovery time was measured using the MDD-2 Macular Degeneration Detection Device. The MDD-2 is a relatively simple device, comprising a spectrally broadband xenon flash light source with good short- (around one per cent) and long-term (around three per cent) output stability, a UV and IR filter and focussing (+8.00 D) lens. The test involves accurate identification (post-flash photostress) of a large (0.41 radian or 23.5°) angular subtense and stroke width of about 2.7°, requiring about 6/120 Snellen acuity (logMAR 1.3), internally presented and randomly generated numbers between zero and nine. The target is viewed through a 12 mm central aperture in the flash tube. The 200 µsec duration flash is generated by a xenon flash source (mouser type FT04050), mounted inside the flash tube within the subject's field of view (flash source to cornea distance of approximately 50 cm) and generates uniform maximum irradiance of 4.5 W/cm² at the viewing aperture across an angular subtense of 0.67 radians (38.4°).

The nature of the test and stimuli were described in detail to each subject and the subjects were requested to confirm their understanding of the task. The test was conducted using natural, undilated pupils in ambient room lighting conditions averaging 870 lux. The flash tube was positioned against the test eye and the subject was required to correctly identify a baseline, pre-photostress, numeric stimulus without their refractive correction. Subjects were instructed to stare into the device at the instant they were ready to begin the test, to fixate centrally at the position of the pre-bleach stimulus and to avoid blinking at the onset of the photostress flash. When ready to commence the test proper, the subject pressed a button on the device, which initiated three concurrent processes; the arc flash photostress, the photostress recovery timer and a new random number display. Once vision recovered sufficiently to allow number recognition, the subject was required to verbally identify the new number and simultaneously, to press the same button on the device to cease the test. The actual number presented by the device and the

subject's PSRT were vocally confirmed by the device, allowing the examiner to determine the accuracy of the subject response and to record the PSRT. Three successive measurements (PSRT 1, PSRT 2 and PSRT 3), separated by two-minute intervals (determined as a sufficient time interval to allow retinal recovery during a pilot study) were recorded for the subject's dominant eye (determined using the Miles Test).³¹ One further reading was taken using the non-dominant eye (PSRT 4). Incorrect identification of the test stimulus at baseline resulted in exclusion from the study. A single incorrect response during the test phase was permitted (result discarded and test repeated following a two-minute interval) but a second incorrect response resulted in exclusion from the study.

The statistical software package SPSS (version 18) was used for analysis (SPSS Inc., Chicago, IL, US). A linear regression analysis was used to assess for an effect of age, sex and iris colour on photostress times. Pearson correlation coefficients were calculated to investigate the relationship between sequential measurements and between eyes. Bland-Altman analysis and plots, as well as the limits of agreement, were used to quantify the agreement between repeat measures of the PSRT. Intra-measurement repeatability is expressed as a coefficient of repeatability, which was calculated as the standard deviation of the mean difference between measurements and multiplied by 1.96. Repeated measures analysis of variance (ANOVA) was conducted to test for a learning or fatigue effect that might confound the test-retest analysis. A five per cent significance level was used throughout the analysis.

RESULTS

The mean age (\pm SD) of the sample was 35 ± 8 years and ranged from 18 to 66 years. The mean VA was logMAR -0.04 ± 0.06 . The mean PSRT for each of the three measurements in the dominant eye and the final measurement in the fellow eye are presented in Table 1. They demonstrate a trend toward improved PSRT with each sequential measurement in the

Photostress measurement (eye)	Mean \pm SD PSRT (seconds)	Range (seconds)
PSRT 1 (Dominant)	7.37 \pm 3.2	3–24
PSRT 2 (Dominant)	5.50 \pm 1.70	3–10
PSRT 3 (Dominant)	5.11 \pm 1.51	3–11
PSRT 4 (Non-dominant)	5.83 \pm 1.72	1–12

SD = standard deviation

Table 1. Mean photostress recovery times (PSRT) for the first (PSRT 1), second (PSRT 2) and third (PSRT 3) measurements of the dominant eye of participants and mean PSRT of the non-dominant eye (PSRT 4).






Figure 1. Correlation between (A) photostress recovery time for the second (PSRT 2) and third (PSRT 3) measurements of the dominant eye and (B) photostress recovery time for the second (PSRT 2) measurement of the dominant eye and the first measurement of the non-dominant eye (PSRT 4)

dominant eye, with the most substantial improvement in PSRT occurring between PSRT 1 and PSRT 2.

Repeated measures ANOVA, using a general linear model approach, with age, sex and iris colour as co-variables, confirmed the presence of an intra-

measurement learning effect ($p < 0.001$), as demonstrated by a gradual shortening of successive PSRT measures in the dominant eye. Pearson's correlation revealed a moderate and significant relationship between PSRT 2 and PSRT 3 in the dominant eye ($r = 0.66$; $p < 0.01$; Figure 1a) and



1 **Figure 2. Bland–Altman plot showing 95 per cent limits of**
2 **agreement for repeat measurements in the dominant eye (PSRT**
3 **2 and PSRT 3)**

38 **Figure 3. Bland–Altman plot showing 95 per cent limits of**
39 **agreement for repeat measurements between eyes (PSRT 2 and**
40 **PSRT 4)**

4
5 a similarly significant inter-eye correlation
6 ($r = 0.58$; $p < 0.01$; Figure 1b), indicating
7 good within- and between-eye associations
8 for repeated measures.

9 Bland–Altman analysis and plots were
10 used to assess intra- and inter-eye agree-
11 ment. The difference in mean recovery
12 time between PSRT 2 and PSRT 3 in the
13 dominant eye (0.39 seconds) and limits of
14 agreement are presented in Figure 2. A
15 paired t-test revealed a significant differ-
16 ence in PSRT between repeat measures of
17 the same eye ($t = 2.93$, $p = 0.004$), indicat-
18 ing a bias toward shorter recovery times in
19 PSRT 3. The coefficient of repeatability in
20 the dominant eye was 2.61 seconds and for
21 76 per cent of subjects, the difference in
22 recovery time between PSRT 2 and PSRT 3
23 was one second or less, indicating good
24 within-eye repeatability. When comparing
25 both PSRT 2 and PSRT 3 with PSRT 1, the
26 coefficients of repeatability were signifi-
27 cantly poorer at 4.69 seconds (PSRT 2)
28 and 5.67 seconds (PSRT 3), respectively.
29 In addition, differences between recorded
30 recovery times were one second or less for
31 only 49 per cent (PSRT 1 versus PSRT 2)
32 and 37 per cent (PSRT 1 versus PSRT 3) of
33 subjects, indicating poorer repeatability,
34 when using the initial PSRT 1 as the base-
35 line value.
36
37

The inter-eye difference between mean
PSRT 2 and PSRT 4 (0.33 seconds) and
limits of agreement are presented in
Figure 3. A paired t-test revealed a signifi-
cant difference in PSRT between eyes ($t =$
 2.24 , $p = 0.028$), indicating a bias toward
longer recovery times in the fellow, non-
dominant eye. The coefficient of repeat-
ability for between eye measurements was
3.19 seconds and 67 per cent of subjects
exhibited an inter-eye difference of one
second or less, indicating good repeatabil-
ity between eyes.

DISCUSSION

Although available evidence suggests that
PSRT is sensitive to diseases like early
AMD, it is little used in clinical practice.
Despite its clinical simplicity and ability to
detect worsening pathology even before
ophthalmoscopic manifestations,²⁷ the
macular photostress recovery test has not
been widely used by clinicians for several
reasons, typically due to the inherent
variability of previous tests (for example,
providing a single standard for an
ophthalmoscopy-based technique would
be almost impossible as the expected
degree of photostress would vary with
battery charge level, light bulb type and

letter chart variability),³² as well as diffi-
culty implementing such tests into routine
clinical practice (for example, the use of a
perimeter to measure the recovery of sensi-
tivity following photostress still requires
an additional photostress source or
alternatively, a non-standard perimetric
routine).²⁸

A legitimate criticism of the PSRT
concept is the lack of any standardised test
for the PSRT or clinical guidelines for
implementation and interpretation, which
can be used to reliably and efficiently
provide an indicator of functional visual
status and its relation to retinal and
macular disease and perhaps to cata-
racts.³³ Numerous devices including the
Scotometer,³⁴ the Brightness Acuity Test
(BAT)³⁵ and the Eger Macular Stressom-
eter³⁶ have been developed but not
adopted for routine clinical practice.
Device adaptations have also been used to
provide a PSRT, using instruments such as
the ophthalmoscope,³² the electroretino-
gram²⁵ and the automated perimeter.²⁸ No
device or technique has proved capable
of providing a clinically acceptable gold
standard measure of PSRT that is widely
applicable and acceptable to routine clinical
practice. The current results advance
the possibility that the MDD-2 could

1 provide such a measure, although it
2 remains premature to definitively con-
3 clude this.

4 The current study was designed to evalu-
5 ate the repeatability of the MDD-2 within a
6 single clinical session to determine:

- 7 1. whether a substantial practise session
8 would be required before a reliable
9 and repeatable baseline measure of
10 PSRT could be determined among
11 naïve subjects and
- 12 2. the degree of inter-eye symmetry that
13 might be expected among normal sub-
14 jects, which could provide an indica-
15 tion of the capacity of the device to
16 detect unilateral or asymmetric bilat-
17 eral pathology, such as central serous
18 retinopathy or AMD (as an asymmetric
19 PSRT) at a single visit.

20 Although the device is marketed as an
21 AMD detection tool, it is likely that optom-
22 etrists and eye-care practitioners would
23 use the device routinely for 'normal'
24 patients, both as an added ocular health
25 check and as part of any preventive health
26 or screening strategy for AMD. Therefore,
27 it is essential that the device is first tested
28 for repeatability and ease of use among a
29 normal population, which represents the
30 aim of the current study.

31 Statistical analysis reveals a significant
32 learning effect and difference between
33 repeat measures of PSRT both within and
34 between eyes. The significance of these
35 differences is of clinical relevance only for
36 the PSRT 1 measurement, which is consid-
37 erably more variable (the standard devia-
38 tion and range of PSRT measures are two
39 to three times larger than in any of the
40 three subsequent measurements), and
41 considerably slower (up to 44.2 per cent
42 slower on average) than subsequent meas-
43 ures. The small variations observed among
44 PSRT 2, PSRT 3 and PSRT 4 are certainly
45 not clinically significant relative to the dra-
46 matically increased PSRT observed previ-
47 ously in patients with AMD or diabetic
48 maculopathy compared to normal con-
49 trols using the same device.²⁰

50 Typically it might be expected that
51 repeat testing at short two-minute intervals
52 would cause further bleaching of photo-
53 pigment and consequential delays in
54 PSRT in normal, but particularly, in dis-

eased retinae. The observation here that
PSRT remains stable in normal eyes,
despite such short repeat test intervals is of
interest and may offer further diagnostic
potential. The typical PSRT observed is so
short and the repeat test values so stable
that it is not unreasonable to speculate
that the device might predominantly test
neural recovery mechanisms rather than
the mechanics of photopigment bleaching
and recovery. Perhaps this could be con-
sidered a 'flash' variation of traditional
nyctometric techniques, which evaluate
the initial two minutes of macular recovery
dynamics in response to sustained expo-
sure to a bright light source.³⁸

It has been shown previously that the
dynamics of short-term macular recovery
are impaired in diabetic retinopathy.^{38,39}
Therefore, it is plausible to suggest that
short interval repeat testing could itself
reveal early retinal and macular functional
loss. This would manifest as deterioration
in PSRT, compared to the initial PSRT
measurement, on repeated short interval
testing not seen in normal observers here.
Of course, this is purely speculative at this
stage but might represent a useful further
investigation into the clinical applicability
of the MDD-2 device. This device also
appears to be robust to the possible effects
of age or iris colour on PSRT within
this sample population. Iris colour, for
example, might be expected to influence
PSRT, as relatively more light would pass
through a light compared to a dark iris.³⁷
It appears that the small amount of light
that could traverse the lightest of irides
does not play a role in determining PSRT.

These combined results suggest that a
single practise measurement is sufficient
to overcome any learning effect. Further-
more, the degree of inter-eye symmetry
observed suggests the MDD-2 may have
the capacity to detect unilateral or asym-
metric pathology, as a delayed PSRT in
one eye. The capacity of a device to
provide repeatable measurements does
not provide absolute evidence that such a
device can differentiate normal from dis-
eased eyes. For example, the Eger Macular
Stressometer is incapable of providing
information regarding AMD severity or
progression.³⁶ The MDD-2 is capable²⁰ of:

1. differentiating normal from AMD-
affected eyes (PSRT doubled on
average in early AMD)
2. differentiating early and late forms of
AMD (PSRT doubled on average in late
compared to early stages) and
3. detecting disease progression (in
AMD and diabetic maculopathy) in the
absence of other clinical signs of dete-
rioration of visual acuity and Amsler
grid findings.

These findings suggest that the MDD-2
is sensitive to subtle changes in macular
health, despite the test design, which
would not seem appropriate for the isola-
tion of specific macular function (the
target and photostress areas extend signifi-
cantly beyond the macula). Such design
features could prove advantageous by
extending the usefulness of the device for
non-macular disease, which may impact
PSRT, such as cataract or glaucoma,
although this concept remains to be
tested).

Therefore, it appears that an instru-
ment based on the principles of the
MDD-2 provides a reliable and user-
friendly means to assess ocular health in
routine practice. The test is easily under-
stood and consequently requires only a
verbal description of the task, followed by
a single practise demonstration in one eye,
for naïve users to reach a learning plateau
and provide repeatable measures of PSRT.
Given the statistical significance of the
differences in repeat measures between
eyes, it would seem prudent to include a
practise measurement routinely in each
eye before valid clinical measures are
recorded. Such valid measures will serve as
the baseline for serial measurements of
PSRT. The results of the current study
suggest that deterioration of greater
than three seconds in measurements
of photostress recovery over time should
be regarded as somewhat suspicious,
although this concept warrants further
detailed and longitudinal studies.

The results cannot be generalised to a
specifically older population, which might
exhibit relatively slower normal PSRT²⁰
and more variability in PSRT due condi-
tions such as age-related cataracts.³³ As
such, the repeatability of the test among

an older population more likely affected by AMD would require additional investigation. Furthermore, the device has yet to be proven capable of detecting the earliest signs of disease or to detect changes in PSRT within individuals over time as a consequence of disease.

Although the MDD-2 device has been designed and marketed as an AMD tool, the current study suggests that it would be of clinical value to incorporate this test into routine clinical practice for all patients. The simplicity, short duration and diagnostic capacity of the test further enhance the concept that it could become an important and routinely-used clinical test of functional macular and central retinal integrity that can readily provide a clinical biomarker of ocular health, disease progression and disease severity.

REFERENCES

1. Congdon N, O'Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, Kempen J et al. Causes and prevalence of visual impairment among adults in the United States. *Arch Ophthalmol* 2004; 122: 477–485.

2. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. *Arch Ophthalmol* 1998; 116: 653–658.

3. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. *Bull World Health Organ* 2004; 82: 844–851.

4. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? *Br J Ophthalmol* 2003; 87: 312–317.

5. Kelliher C, Kenny D, O'Brien C. Trends in blind registration in the adult population of the Republic of Ireland 1996–2003. *Br J Ophthalmol* 2006; 90: 367–371.

6. Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). *Optometry* 2004; 75: 216–230.

7. The CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe CJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *N Engl J Med* 2011; 364: 1897–1908.

8. Hogg RE, Chakravarthy U. Visual function and dysfunction in early and late age-related maculopathy. *Prog Ret Eye Res* 2006; 25(3): 249–276.

9. Feigl B, Greaves A, Brown B. Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity. *Clin Ophthalmol* 2007; 1: 167–175.

10. Meleth AD, Mettu P, Agrón E, Chew EY, Sadda SR, Ferris FL, Wong WT. Changes in retinal sensitivity

in geographic atrophy progression as measured by microperimetry. *Invest Ophthalmol Vis Sci* 2011; 52: 1119–1126.

11. Gin TJ, Luu CD, Guymer RH. Central retinal function as measured by the multifocal electroretinogram and flicker perimetry in early age-related macular degeneration. *Invest. Ophthalmol Vis Sci* 2011; 52: 9267–9374.

12. O'Neill-Biba M, Sivaprasad S, Rodriguez-Carmona M, Wolf JE, Barbur JL. Loss of chromatic sensitivity in AMD and diabetes: a comparative study. *Ophthalmic Physiol Opt* 2010; 30: 705–716.

13. Monés J, Rubin GS. Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration. *Eye* 2005; 19: 1142–1150.

14. Haegerstrom-Portnoy G. Short wavelength sensitive-cone sensitivity with aging: a protective role for macular pigment? *J Opt Soc Am* 1988; 5: 2140–2144.

15. Gaffney AJ, Binns AM, Margrain TH. Topography of cone dark adaptation deficits in age-related maculopathy. *Optom Vis Sci* 2011; 88: 1080–1087.

16. Dimitrov PN, Robman L, Varsamidis M, Aung KZ, Makeyeva GA, Guymer RH, Vingrys AJ. Visual function tests as potential biomarkers in age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2011; 52: 9457–9469.

17. Loughman J, Davison PA, Nolan JM, Akkali MC, Beatty S. Macular pigment and its contribution to visual performance and experience. *J Optom* 2010; 3: 74–90.

18. Bernstein PS, Delori FC, Richer S, van Kuijk FJ, Wensel AJ. The value of measurement of macular carotenoid pigment optical densities and distributions in age-related macular degeneration and other retinal disorders. *Vision Res* 2010; 50: 716–728.

19. Beatty S, Murray IJ, Henson DB, Carden D, Koh H, Boulton ME. Macular pigment and risk for age-related macular degeneration in subjects from a northern European population. *Invest Ophthalmol Vis Sci* 2001; 42: 439–446.

20. Newsome DA, Negreiro M. Reproducible measurement of macular light flash recovery time using a novel device can indicate the presence and worsening of macular disease. *Curr Eye Res* 2009; 34: 162–170.

21. Neelam K, Nolan J, Chakravarthy U, Beatty S. Psychophysical function in age-related maculopathy. *Surv Ophthalmol* 2009; 54: 167–210.

22. Lacey JA, Jacobs RJ. The macular photostress test. *Aust J Optom* 1983; 66: 147–150.

23. Stringham JM, Bovier ER, Wong JC, Hammond BR Jr. The influence of dietary lutein and zeaxanthin on visual performance. *J Food Sci* 2010; 75: 24–29.

24. Magder H. Test for central serous retinopathy based on clinical observations and trial. *Am J Ophthalmol* 1960; 49: 147–150.

25. Binns AM, Margrain TH. Evaluating retinal function in age-related maculopathy with the ERG photostress test. *Invest Ophthalmol Vis Sci* 2007; 48: 2806–2813.

26. Glaser JS, Savino PJ, Summers KD, McDonald SA, Knighton RW. The photostress recovery test in the clinical assessment of visual function. *Am J Ophthalmol* 1977; 83: 255–260.

27. Roy MS. Vision loss without Amsler grid abnormalities in macular subretinal neovascularization. *Ophthalmologica* 1985; 191: 215–217.

28. Dhalla MS, Fantin A. Macular photostress testing: Sensitivity and recovery with an automated perimeter. *Retina* 2005; 25: 189–192.

29. Owsley C, McGwin G, Jackson G, Heimburger DC, Piyathilake CJ, Klein R, White MF et al. Effect of short-term, high dose retinol on dark adaptation in aging and early age-related maculopathy. *Invest Ophthalmol Vis Sci* 2006; 47: 1310–1318.

30. Seddon JM, Sahagian C, Glynn R, Sperduto RD, Gragoudas ES. Evaluation of an iris color classification system. *Invest Ophthalmol Vis Sci* 1990; 31: 1592–1598.

31. Roth HL, Lora AN, Heilman KM. Effects of monocular viewing and eye dominance on spatial attention. *Brain* 2002; 125: 2023–2035.

32. Margrain TH, Thomson D. Sources of variability in the clinical photostress test. *Ophthalmic Physiol Opt* 2002; 22: 22–27.

33. Michael R, van Rijn LJ, van den Berg TJTP, Barraquer RI, Grabner G, Wilhelm H, Coeckelbergh T et al. Association of lens opacities, intraocular straylight, contrast sensitivity and visual acuity in European drivers. *Acta Ophthalmol* 2009; 87: 666–671.

34. Henkind P, Siegel IM. The scotometer: a device for measuring macular recovery time. *Am J Ophthalmol* 1967; 64: 314–315.

35. Nousiainen I, Kalviainen R, Mantjarvi M. Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers. *Br J Ophthalmol* 2000; 84: 622–625.

36. Wolffsohn J, Anderson SJ, Mitchell J, Woodcock A, Rubinstein M, Flytche T, Browning A et al. Effect of age-related macular degeneration on the Eger macular stressometer photostress recovery time. *Br J Ophthalmol* 2006; 90: 432–434.

37. van den Berg TJTP, Ijsepeert JK, de Waard PW. Dependence of intraocular straylight on pigmentation and light transmission through the ocular wall. *Vision Res* 1991; 31: 1361–1367.

38. Frost-Larsen K, Larsen HW. Macular recovery time recorded by nyctometry—a screening method for selection of patients who are at risk of developing proliferative diabetic retinopathy. *Arch Ophthalmol* 1985; 63 (suppl 173): 39–47.

39. Midena E, Segato C, Giuliano M, Zucchetto M. Macular recovery function (nyctometry) in diabetics with and without retinopathy. *Br J Ophthalmol* 1990; 74: 106–108.